Discriminatory Value of the Revised Risk Analysis Index Compared With the Charlson Comorbidity Index in Predicting Outcomes of Patients Undergoing Treatment for Chronic Subdural Hematoma

RAI-rev outperforms CCI in predicting outcomes for patients undergoing surgical and/or endovascular treatment for cSDH. Including RAI-rev during preoperative evaluation may enhance risk stratification and guide treatment planning, including consideration of less invasive interventions in frail patients. Furthermore, integrating RAI-rev into future clinical trials studying patients with cSDH may allow for better understanding of frailty metrics and capture of clinical variables that can affect patient outcomes.